• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ovid Therapeutics Inc (NQ: OVID )

    0.7201 +0.0075 (+1.05%)
    Streaming Delayed Price Updated: 1:31 PM EDT, Jun 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ovid Therapeutics Inc

    Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Participate in Upcoming September Investor Conferences
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Added to Russell 3000® Index
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
    A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options 
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.